

Prior Authorization Request Form Fax Back To: (866) 940-7328

Phone: (800) 310-6826

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient's Name:							
Insurance ID: Date of Birth: Height: Weight:							
Address: Apartment #:							
City: State: Zip Code:							
Phone Number: Alternate Phone: Sex: Male Fema	le						
Provider Information							
Provider's Name: Provider ID Number:							
Address: City: State: Zip Code:							
Suite Number: Building Number:							
Phone Number: Fax number:							
Provider's Specialty:							
Medication Information							
Medication: Quantity: ICD10 Code:							
Directions: Diagnosis: Refills:							
Physician Signature**: Initial here if DAW:							
Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.							
Medication Instructions							
Has the patient been instructed on how to Self-Administer ? ☐ Yes ☐ No							
Is this medication a New Start ?							
If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /							
Is there documentation of positive clinical response to current therapy?							
**Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.							
Delivery Instructions							
Delivery instructions	Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information" Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery						
Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"							
Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"							



Iclusig - Washington

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A - Member Inforn	nation						
First Name:		Last Name	e:		Member ID:		
Address:							
City:		State:			ZIP Code:		
Phone:		DOB:			Allergies:	Allergies:	
Primary Insurance Information:				,			
Is the requested medication	n 🗆 New or 🗆 C	Continuation	on of Therapy? If c	ontinuation, list	start date:		
Is this patient currently hos	-	Yes □ No	If recently discha	rged, list discha	arge date: _		
Section B - Provider Inform	nation		Last Name:			M D /D O	
First Name:					01.1.	M.D./D.O.	
Address:			City:		State:	ZIP code:	
Phone:	Fax:		NPI #:		Specialty:		
Office Contact Name / Fax a	ttention to:						
Section C - Medical Inform Medication:	ation				Strength	:	
Directions for use:					Quantity	:	
Diagnosis (Please be speci	fic & provide as	much info	rmation as possible)	:	ICD-10 (CODE:	
Is this member pregnant?	□ Yes □ No	If yes	s, what is this mem	ber's due date?			
Section D - Previous Medi	cation Trials						
	cation Trials	If yes	o, what is this mem	ber's due date? Dates of The	rapy Re	eason for failure /	
Section D - Previous Medi	cation Trials				rapy Re		
Section D - Previous Medi	cation Trials				rapy Re		
Section D - Previous Medi	cation Trials				rapy Re		
Section D - Previous Medi	cation Trials				rapy Re		
Section D – Previous Medinations	cation Trials Stre	ngth	Directions	Dates of The	rapy Re	discontinuation	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	
Section D – Previous Medinal Medications Section E – Additional infor	cation Trials Stre	ngth	Directions of why preferred m	Dates of The	rapy Re	the patient's needs:	



Physician Signature:

Iclusig - Washington

PRIOR AUTHORIZATION REQUEST FORM

Date:

Member First name:		Member Last name:	Member DOB:			
Clinical and Drug Specific Information						
ALL REQUESTS						
□ Yes □ No	Does the patient have any of the following diagnoses? (If yes, check which applies) □ Chronic myelogenous/myeloid leukemia (CML) □ Philadelphia chromosome positive acute lymphoblastic leukemia (Ph +ALL)					
□ Yes □ No	Is there confirmed documentation of T315I mutation?					
□ Yes □ No	Is the patient unable to take, or has failed treatment with, two or more tyrosine kinase inhibitor (TKI) therapies [e.g., imatinib mesylate, Sprycel (dasatinib), or Tasigna (nilotinib)]? (If yes, complete section D above)					
□ Yes □ No	Is Iclusig being requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium? If yes, list supported use:					
	PI	HILADELPHIA CHROMOSOME (PH +AL	L)			
□ Yes □ No	Will Iclusig be used in combination with an induction regimen not previously used? If yes, list regimen:					
□ Yes □ No	Will Iclusig be used as a component of Hyper-CVAD (hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine) induction or consolidation?					
□ Yes □ No	Will Iclusig be used as maintenance therapy in combination with vincristine and prednisone with or without methotrexate and mercaptopurine? (If yes, complete section D above)					
□ Yes □ No	Will Iclusig be used as maintenance therapy post-hematopoietic stem cell transplant?					
CONTINUATION OF THERAPY						
□ Yes □ No	Does the patient show ev	vidence of progressive disease while o	n Iclusig therapy?			
□ Yes □ No	Does the patient have a documented positive clinical response to Iclusig therapy? If yes, list response:					

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.